Cue Biopharma Raises $30M, Earns $7.5M Milestone, Licenses CUE-221 and Preps INDs
CUE•Cue Biopharma reported first‐quarter revenue of $5.7 million, cut net loss to $5.2 million from $12.3 million and held $16.4 million cash. It secured a $30 million private placement, a $7.5 million milestone payment, licensed CUE-221 and plans IND filings for CUE-221 and CUE-401.
1. First Quarter Financial Performance
Cue Biopharma posted revenue of $5.7 million in Q1 2026 compared to $0.4 million in Q1 2025, primarily from the Boehringer Ingelheim collaboration. Research and development expenses decreased to $6.9 million while general and administrative costs remained flat at $4.2 million, resulting in a net loss of $5.2 million versus $12.3 million last year. The company held $16.4 million in cash and equivalents at March 31.
2. Pipeline Expansion and Upcoming Milestones
The company secured an exclusive license for CUE-221, a late-stage anti-IgE candidate targeting allergic diseases, and showcased CUE-401, a bifunctional IL-2/TGF-β program for autoimmune indications. Cue plans to file IND applications for both assets in the second half of 2026, with a global Phase 2b food allergy trial for CUE-221 and a first-in-human Phase 1 study for CUE-401 slated to follow.
3. Financing and Balance Sheet Strength
Cue completed a private placement of pre-funded warrants and common warrants raising $30 million (net $28 million) and received a $7.5 million milestone payment under its Boehringer Ingelheim collaboration. These proceeds, combined with existing cash, strengthen the balance sheet to support planned clinical milestones through late-stage development.
4. Leadership Appointment and Strategic Direction
Shao-Lee Lin, M.D., Ph.D., was appointed President, CEO and board director to lead Cue’s transformation into a clinical-stage company. With 25 years of immunology experience and a track record of building multi-billion-dollar portfolios, Lin will oversee execution of the enhanced pipeline and drive value-creating milestones.
